Table 1.

Patient characteristics and molecular results obtained with Idylla™ GeneFusion and reference method in the assessment of ALK, ROS1, RET translocations and MET ex14 skipping.

Case n.	Sex/Age	Histological Type	Tissue Alteration RTPCR/NGS	MPE %Tumor Cells *	MPE/cfRNA Conc. (ng/µL)	MPE/cfRNA RTPCR°/NGS§	MPE/Idylla	Idylla Cytological Smear **
1	M/54	ADK	ALK+	7.0%	8	ALK+°§	ALK+@	ALK−
2	M/85	ADK	RET+	95.0%	99	RET+°§	RET+	RET+
3	M/63	ADK	ALK+	5.0%	38	ALK+°§	ALK+	ALK+
4	M/64	ADK	ALK+	60.0%	10.4	ALK+°§	ALK+@	ALK+
5	F/64	ADK	ALK+	60.0%	17	ALK+°§	ALK+@	ALK+
6	M/64	ADK	ALK+	50.0%	89	ALK+°§	ALK+	ALK+
7	F/70	ADK	ROS1+	50.0%	11.2	ROS1+°§	ROS1+	N.A.
8	M/65	ADK	Met skip+	N.A.	N.A.	N.A.	Met skip+	N.A.
9	F/76	ADK	RET+	88.0%	6.5	RET+°§	RET+	N.A.

Abbreviations: M: male; F: female; ADK: adenocarcinoma; +: positive; −: negative; N.A.: not applicable; * % was evaluated in cytological smear sample obtained from MPE; ** cells from MPE/smears were scraped and loaded on the Idylla cartridge. @ presence of a 5′-3′ expression imbalance of the gene. § NGS, ° RTPCR